Frontlight ResearchEarly access
WithdrawnPhase 4
Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients
Key facts
- Who runs it
- University of Illinois Chicago
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 4
- Started
- 1 Jan 2023
- Ended
- 1 Jan 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- Imipenem/Cilastatin/Relebactam 1.25g
- Record updated
- 27 November 2024
- Why it stopped
- Investigator is no longer at University of Illinois
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age ≥18 years of age
- Admitted to the ICU
- BMI ≥40 kg/m2 and/or total body weight ≥120 kg
- Provide a signed and dated written informed consent prior to study participation
Who cannot take part
- History of seizures and/or receiving 1 or more anti-epileptic agent
- Actively receiving antimicrobial therapy for treatment of a confirmed or suspected infection
- The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days prior to the first dose of study medication
- Has previously participated in this study
- History of significant hypersensitivity reaction or intolerance to imipenem/cilastatin or carbapenem-based agents (doripenem, ertapenem, or meropenem +/- vaborbactam)
- Any other condition that may make the patient unsuitable for the study in the judgement of the investigator
- Serum creatinine ≥1.5 mg/dL
- Estimated creatinine clearance (CLCR) <60 mL/minute as determined by Cockcroft-Gault equation:
- Positive serum pregnancy test (for women of childbearing potential)
- Concomitant use of valproic acid or divalproex sodium
- Currently breast feeding
Where in United States
- University of Illinois at ChicagoChicago, United States
About the trial
What the trial wants to find out
This study is an open-label, multiple-dose pharmacokinetic study of imipenem-relebactam conducted in 12 non-infected, obese ICU patients.
The 2 groups in the trial
- Pharmacokinetic cohortTreatment being tested
After at least 2 doses of study drug, serial blood samples will be collected from 12 non-infected, obese ICU patients to evaluate the pharmacokinetics of imipenem and relebactam in this population.
Treatment: Imipenem/Cilastatin/Relebactam 1.25g
- Safety cohortTreatment being tested
After at least 2 doses of study drug, safety will be monitored closely during study drug dosing and through 72 hours after the last dose is administered in the same 12 non-infected, obese ICU patients from the PK arm
Treatment: Imipenem/Cilastatin/Relebactam 1.25g
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 27 November 2024